67 related articles for article (PubMed ID: 19969344)
1. Sustained release of ganciclovir and foscarnet from biodegradable scleral plugs for the treatment of cytomegalovirus retinitis.
Peng YJ; Wen CW; Chiou SH; Liu SJ
Biomaterials; 2010 Mar; 31(7):1773-9. PubMed ID: 19969344
[TBL] [Abstract][Full Text] [Related]
2. In vitro elution of vancomycin/amikacin/steroid from solvent-free biodegradable scleral plugs.
Liu SJ; Kau YC; Liaw CW; Peng YJ
Int J Pharm; 2009 Mar; 370(1-2):75-80. PubMed ID: 19101617
[TBL] [Abstract][Full Text] [Related]
3. Scleral plug of biodegradable polymers containing ganciclovir for experimental cytomegalovirus retinitis.
Sakurai E; Matsuda Y; Ozeki H; Kunou N; Nakajima K; Ogura Y
Invest Ophthalmol Vis Sci; 2001 Aug; 42(9):2043-8. PubMed ID: 11481270
[TBL] [Abstract][Full Text] [Related]
4. Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis.
Aweeka FT; Gambertoglio JG; Kramer F; van der Horst C; Polsky B; Jayewardene A; Lizak P; Emrick L; Tong W; Jacobson MA
Clin Pharmacol Ther; 1995 Apr; 57(4):403-12. PubMed ID: 7712668
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical localization of ganciclovir in the human retina.
Park SS; Girard B; Font RL; Hauw JJ; Young LH
Curr Eye Res; 1998 Jun; 17(6):663-7. PubMed ID: 9663857
[TBL] [Abstract][Full Text] [Related]
6. Biodegradable polymeric device for sustained intravitreal release of ganciclovir in rabbits.
Hashizoe M; Ogura Y; Takanashi T; Kunou N; Honda Y; Ikada Y
Curr Eye Res; 1997 Jul; 16(7):633-9. PubMed ID: 9222079
[TBL] [Abstract][Full Text] [Related]
7. Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir.
Jabs DA
Infect Agents Dis; 1995 Sep; 4(3):131-42. PubMed ID: 8548191
[TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of polymeric matrix and porous biodegradable reservoir devices for slow-release drug delivery.
Peyman GA; Yang D; Khoobehi B; Rahimy MH; Chin SY
Ophthalmic Surg Lasers; 1996 May; 27(5):384-91. PubMed ID: 8860606
[TBL] [Abstract][Full Text] [Related]
9. Toxicologic and pharmacokinetic analysis of intravitreal injections of foscarnet, either alone or in combination with ganciclovir.
Berthe P; Baudouin C; Garraffo R; Hofmann P; Taburet AM; Lapalus P
Invest Ophthalmol Vis Sci; 1994 Mar; 35(3):1038-45. PubMed ID: 8125715
[TBL] [Abstract][Full Text] [Related]
10. Solvent-free biodegradable scleral plugs providing sustained release of vancomycin, amikacin, and dexamethasone--an in vivo study.
Peng YJ; Kau YC; Wen CW; Liu KS; Liu SJ
J Biomed Mater Res A; 2010 Aug; 94(2):426-32. PubMed ID: 20186737
[TBL] [Abstract][Full Text] [Related]
11. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group.
Arch Intern Med; 1995 Jan; 155(1):65-74. PubMed ID: 7802522
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits.
López-Cortés LF; Pastor-Ramos MT; Ruiz-Valderas R; Cordero E; Uceda-Montañés A; Claro-Cala CM; Lucero-Muñoz MJ
Invest Ophthalmol Vis Sci; 2001 Apr; 42(5):1024-8. PubMed ID: 11274081
[TBL] [Abstract][Full Text] [Related]
13. Intraocular therapy for cytomegalovirus retinitis.
Palestine AG
J Int Assoc Physicians AIDS Care; 1996 May; 2(5):25-8. PubMed ID: 11363527
[TBL] [Abstract][Full Text] [Related]
14. Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis.
Kunou N; Ogura Y; Yasukawa T; Kimura H; Miyamoto H; Honda Y; Ikada Y
J Control Release; 2000 Aug; 68(2):263-71. PubMed ID: 10925134
[TBL] [Abstract][Full Text] [Related]
15. Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis.
Sakurai E; Nozaki M; Okabe K; Kunou N; Kimura H; Ogura Y
Invest Ophthalmol Vis Sci; 2003 Nov; 44(11):4845-52. PubMed ID: 14578407
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of severe cytomegalovirus retinitis with foscarnet and intraocular injection of ganciclovir in a myelosuppressed unrelated bone marrow transplant patient.
Okamoto T; Okada M; Mori A; Saheki K; Takatsuka H; Wada H; Tamura A; Fujimori Y; Takemoto Y; Kanamaru A; Kakishita E
Bone Marrow Transplant; 1997 Nov; 20(9):801-3. PubMed ID: 9384487
[TBL] [Abstract][Full Text] [Related]
17. Therapy with a combination of intravitreal foscarnet and intravenous ganciclovir in clinically resistant cytomegalovirus retinitis and patients with acquired immunodeficiency syndrome.
Guembel HO; Hofmann F; van Even G; Cinatl J; Makabe R
Ger J Ophthalmol; 1996 Nov; 5(6):490-1. PubMed ID: 9479542
[No Abstract] [Full Text] [Related]
18. Biodegradable scleral implant for intravitreal controlled release of ganciclovir.
Yasukawa T; Kimura H; Kunou N; Miyamoto H; Honda Y; Ogura Y; Ikada Y
Graefes Arch Clin Exp Ophthalmol; 2000 Feb; 238(2):186-90. PubMed ID: 10766290
[TBL] [Abstract][Full Text] [Related]
19. Foscarnet or ganciclovir for treatment of AIDS and CMV retinitis.
Moyle G; Gazzard BG
Am J Med; 1995 Mar; 98(3):319-20. PubMed ID: 7872356
[No Abstract] [Full Text] [Related]
20. Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-O-hexadecylpropanediol-3-phospho-ganciclovir.
Cheng L; Hostetler KY; Chaidhawangul S; Gardner MF; Beadle JR; Toyoguchi M; Bergeron-Lynn G; Freeman WR
Invest Ophthalmol Vis Sci; 2002 Feb; 43(2):515-21. PubMed ID: 11818399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
